Aduro BioTech, Inc. (ADRO) Reaches $6.08 After 4.00% Down Move; Shorts at Venator Materials Plc (VNTR) Raised By 9.6%

February 15, 2018 - By Ellis Scott

Venator Materials Plc (NYSE:VNTR) had an increase of 9.6% in short interest. VNTR’s SI was 2.80 million shares in February as released by FINRA. Its up 9.6% from 2.55 million shares previously. With 2.27M avg volume, 1 days are for Venator Materials Plc (NYSE:VNTR)’s short sellers to cover VNTR’s short positions. The stock decreased 0.55% or $0.12 during the last trading session, reaching $21.74. About 379,286 shares traded. Venator Materials PLC (NYSE:VNTR) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) is a huge mover today! The stock decreased 2.80% or $0.175 during the last trading session, reaching $6.075. About 156,605 shares traded. Aduro BioTech, Inc. (NASDAQ:ADRO) has risen 1.22% since February 15, 2017 and is uptrending. It has underperformed by 15.48% the S&P500.The move comes after 7 months negative chart setup for the $469.62 million company. It was reported on Feb, 15 by Barchart.com. We have $5.83 PT which if reached, will make NASDAQ:ADRO worth $18.78M less.

Among 6 analysts covering Venator Materials (NYSE:VNTR), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Venator Materials had 7 analyst reports since August 28, 2017 according to SRatingsIntel. The firm has “Buy” rating by Goldman Sachs given on Monday, August 28. The firm has “Buy” rating by Nomura given on Monday, August 28. The rating was initiated by Suntrust Robinson on Monday, August 28 with “Buy”. The stock has “Outperform” rating by RBC Capital Markets on Monday, August 28. The stock of Venator Materials PLC (NYSE:VNTR) has “Neutral” rating given on Wednesday, December 6 by Goldman Sachs. The rating was initiated by Barclays Capital with “Equal Weight” on Monday, August 28. The stock of Venator Materials PLC (NYSE:VNTR) has “Overweight” rating given on Monday, August 28 by JP Morgan.

Venator Materials PLC manufactures and markets chemical products worldwide. The company has market cap of $2.31 billion. It operates through two divisions, Titanium Dioxide and Performance Additives. It has a 38.48 P/E ratio. The Titanium Dioxide segment offers titanium dioxide , such as rutile, anatase, and nano TiO2 products for use in coatings, plastics, paper, printing inks, fibers, and food and personal care products.

Among 9 analysts covering Aduro Biotech (NASDAQ:ADRO), 7 have Buy rating, 1 Sell and 1 Hold. Therefore 78% are positive. Aduro Biotech had 19 analyst reports since August 19, 2015 according to SRatingsIntel. On Tuesday, October 20 the stock rating was initiated by Oppenheimer with “Outperform”. The rating was downgraded by Bank of America to “Underperform” on Tuesday, March 15. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 1. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “Buy” rating by H.C. Wainwright on Wednesday, September 27. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “Buy” rating by Roth Capital on Thursday, August 27. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “Buy” rating by Cowen & Co on Tuesday, July 18. Zacks upgraded the stock to “Hold” rating in Thursday, September 3 report. The firm has “Outperform” rating given on Tuesday, May 17 by FBR Capital. TH Capital maintained it with “Buy” rating and $68 target in Tuesday, November 24 report. As per Monday, October 30, the company rating was initiated by Oppenheimer.

Analysts await Aduro BioTech, Inc. (NASDAQ:ADRO) to report earnings on March, 7. They expect $-0.36 EPS, up 18.18% or $0.08 from last year’s $-0.44 per share. After $-0.33 actual EPS reported by Aduro BioTech, Inc. for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts